Drugs used in the prevention and treatment of cardiovascular diseases (such as warfarin, statins and β-blockers) are among the most commonly prescribed medications in the United States. Different individuals display variability in the degree of efficacy and/or rate of adverse drug reactions. According to the American Heart Association, there are 450,000 preventable adverse cases annually. These preventable errors include incorrect or unnecessary prescription, improper dosing, and improper dosing intervals. PGx testing is ideal for patients with cardiovascular health issues because the risk of improper or inadequate prescriptions is high, with fatality rates constantly on the rise.
The pharmacogenomic (PGx) cardiovascular panel provides a comprehensive and accurate investigation into drug-gene and drug-drug interactions for cardiovascular medications based on a patient’s unique genetic makeup.